iZafe Group's Q4 Interim Report: Strong Growth and Expansion Opportunities

iZafe Group AB (publ.) has released its Q4 interim report for the period October-December 2024, highlighting significant growth and expansion opportunities for the company. The report showcases the company's strong performance and strategic initiatives, positioning iZafe Group for continued success in the coming years.



Financial Performance and Key Highlights

* Total revenue for the quarter amounted to 2,751 TSEK, more than doubling compared to the same period last year, primarily driven by hardware sales to the Netherlands.
* Operating result (EBIT) for the quarter amounted to -5,697 TSEK, while operating result before depreciation and amortization (EBITDA) was -4,714 TSEK.
* Result after financial items for the quarter amounted to -5,908 TSEK, with cash flow from operating activities at -178 TSEK.
* Earnings per share for the quarter before/after dilution amounted to -0.02 SEK, with equity per share at the end of the period at 0.04 SEK.
* The solidity at the end of the period amounted to 40.1 percent.

Significant Events and Initiatives

1. Launch of Dosell in Spain with Ti Medi: iZafe Group AB launched Dosell in Spain in collaboration with Ti Medi, making Dosell commercially available in Spain. The partnership aims to improve medication management and patient adherence, with the first units expected to be in use soon.
2. Order for 1,000 Dosell units from TCCN: iZafe Group received an order for 1,000 Dosell units from its Dutch distributor TCCN, valued at approximately 3,000 TSEK. Deliveries will take place in two phases during 2024 and 2025, with expected recurring revenue of up to 400 TSEK per month.
3. Certification of Dosell for Enovation UMO integration: iZafe Group has certified Dosell for integration with Enovation UMO, a leading healthcare platform in 18 countries. This certification enhances Dosell's market position, facilitates easier implementation in the Netherlands, and opens opportunities for expansion into additional markets.
4. Directed share issue and working capital strengthening: iZafe Group has conducted a directed share issue of approximately 9.2 MSEK through the issuance of 46.15 million B-shares at a subscription price of 0.20 SEK per share. The capital will be used to strengthen working capital, accelerate growth, and support the expansion of Dosell and Pilloxa into new markets.
5. 25% increase in billable Dosell units and launch in Spain: iZafe Group has started 2025 strong, with a 25% increase in billable Dosell units, approaching 1,000 active devices. Growth is driven by rising demand in Sweden, Norway, and the Netherlands, while the launch in Spain is planned for February. Product improvements and the recently completed 9.2 MSEK share issue further strengthen the company's growth and goal of achieving cash flow positivity.



Forecast and Future Growth

iZafe Group presents a forecast graph illustrating expected growth in both ARR and active Dosell units over the coming years. By the end of 2024, ARR is expected to reach approximately 1.7 MSEK, reflecting a 326% increase compared to the previous year. In 2025, ARR is projected to reach 10 MSEK by year-end, a 352% increase. Beyond that, ARR is expected to continue growing rapidly, more than eightfold by 2029, when the company anticipates exceeding 85 MSEK.

iZafe Group's Q4 interim report demonstrates the company's strong performance and strategic initiatives, positioning it for continued growth and expansion in the coming years. With a clear path toward an exponential increase in recurring revenue as more units become activated, iZafe Group is well-positioned to achieve its financial goals and create value for shareholders.